Corona virus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are spreading globally on a large scale, threatening the safety of human life seriously, and the world needs effective drugs against COVID-19 urgently. Recently, four oral small molecule drugs have been successfully approved for market to treat patients with early mild COVID-19, they were 3C-like protease (3CLpro) inhibitor, RNA-dependent RNA polymerase (RdRp) inhibitor, monoclonal antibody, androgen receptor inhibitor. This paper briefly summarizes these four types of drugs and reviews their clinical therapeutic effects, characteristics and mechanism of action, to provide some references for the development and usage of drugs for the treatment of COVID-19.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |